Okogen has a total of 26 patents globally, out of which 7 have been granted. Of these 26 patents, more than 76% patents are active. United States of America is where Okogen has filed the maximum number of patents, followed by Singapore and Japan. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Okogen.
Okogen was founded in the year 2015. The Company operates as a biotechnology company. The Company discovers, develops and commercializes therapies for the treatment of diseases.
Do read about some of the most popular patents of Okogen which have been covered by us in this article and also you can find Okogen patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Okogen patent portfolio.
How many patents does Okogen have?
Okogen has a total of 26 patents globally. These patents belong to 3 unique patent families. Out of 26 patents, 20 patents are active.
How Many Patents did Okogen File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
Year of Patents Filing or Grant | Okogen Applications Filed | Okogen Patents Granted |
2023 | – | 1 |
2022 | 2 | 3 |
2021 | 8 | 1 |
2020 | – | 1 |
2019 | 1 | – |
2018 | 2 | – |
2017 | 1 | 1 |
2016 | 12 | – |
How many Okogen patents are Alive/Dead?
How Many Patents did Okogen File in Different Countries?
Countries in which Okogen Filed Patents
Country | Patents |
United States Of America | 4 |
Singapore | 2 |
Japan | 2 |
China | 2 |
Canada | 2 |
South Korea | 2 |
Europe | 2 |
Australia | 2 |
Mexico | 1 |
India | 1 |
Austria | 1 |
South Africa | 1 |
Israel | 1 |
Where are Research Centres of Okogen Patents Located?
The Research Centre for all the Okogen patents is the United States of America.
What Percentage of Okogen US Patent Applications were Granted?
Okogen (Excluding its subsidiaries) has filed 4 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 50.0%.
Below are the key stats of Okogen patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Okogen?
Law Firm | Total Applications | Success Rate |
Knobbe Martens Olson & Bear Llp | 4 | 50.00% |
List of Okogen Patents
Okogen Patents | Title |
US9682130B2 | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
US20230218726A1 | Treatment Of Viral Conjunctivitis |
US20220265783A1 | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
EP3353304B1 | Viral Conjunctivitis Treatment Using Ranpirnase |
EP4138882A1 | Treatment Of Viral Conjunctivitis |
CN108350458B | Treatment Of Viral Conjunctivitis With Leopard Frog Enzymes And/Or Amphibian Enzymes |
CN115996715A | Treatment Of Viral Conjunctivitis |
AU2016326750B2 | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
JP6794454B2 | Treatment Of Viral Conjunctivitis Using Ranpirnase And/Or Amphinase |
JP2023522953A | Treatment Of Viral Conjunctivitis |
KR1020230014701A | Treatment Of Viral Conjunctivitis |
AU2021259787A1 | Treatment Of Viral Conjunctivitis |
CA3180714A1 | Treatment Of Viral Conjunctivitis |
SG10201912974VA | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
KR1020180058791A | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
CA2999514A1 | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
MX405744B | Compositions Including Ranpirnase And/Or Anfinase And Their Uses In The Treatment Of Viral Conjunctivitis. |
IL258237B | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
IN202217066688A | Treatment Of Viral Conjunctivitis |
ZA201802197A | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
US20170258876A1 | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
AT1525160T | Behandlung Von Viraler Konjunktivitis Mit Ranpirnase |
WO2021216909A1 | Treatment Of Viral Conjunctivitis |
WO2019222533A1 | Methods Of Treating Ocular Melanoma |
WO2017053923A1 | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
SG11201802287QA | Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase |
What are Okogen key innovation segments?
What Technologies are Covered by Okogen?
The chart below distributes patents filed by Okogen